Protalix BioTherapeutics ... (PLX)
AMEX: PLX
· Real-Time Price · USD
1.41
-0.12 (-7.84%)
At close: Jun 25, 2025, 3:59 PM
1.41
0.00%
After-hours: Jun 25, 2025, 05:36 PM EDT
-7.84% (1D)
Bid | 1.41 |
Market Cap | 112.25M |
Revenue (ttm) | 59.76M |
Net Income (ttm) | 3.91M |
EPS (ttm) | 0.05 |
PE Ratio (ttm) | 28.2 |
Forward PE | 2.08 |
Analyst | Strong Buy |
Ask | 1.57 |
Volume | 640,754 |
Avg. Volume (20D) | 906,001 |
Open | 1.53 |
Previous Close | 1.53 |
Day's Range | 1.41 - 1.55 |
52-Week Range | 0.82 - 3.10 |
Beta | -0.22 |
Analyst Forecast
According to 0 analyst ratings, the average rating for PLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-40.48%
Protalix BioTherapeutics shares are trading lower ...
Unlock content with
Pro Subscription
3 months ago
+9.38%
Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.

1 month ago · seekingalpha.com
Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (NYSE:PLX ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Moyer – Investor Relations Dror Bashan – President and Chief Executive Offi...

1 month ago · proactiveinvestors.com
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growthProtalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout treatment PRX-115 later this year, as the company builds on momentum from pos...